JOVOLA
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

JOVOLA Trademark

Serial Number: 85261936 • Registration: 4651130

JOVOLA is a trademark filed by VALEANT PHARMACEUTICALS LUXEMBOURG S.À.R.L on March 9, 2011. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

VALEANT PHARMACEUTICALS LUXEMBOURG S.À.R.L (72 trademarks)

13-15 AVENUE DE LA LIBERTÉ
LUXEMBOURG CITY 1931 , LU

Entity Type: 99

Biovail Laboratories International SRL

Welches
Christ Church BB17154 , BB

Entity Type: 99

VALEANT PHARMACEUTICALS IRELAND LIMITED (113 trademarks)

3013 LAKE DRIVE
DUBLIN 24 , IE

Entity Type: 99

BAUSCH HEALTH IRELAND LIMITED (241 trademarks)

Dublin 24 , IE

Entity Type: 99

VALEANT INTERNATIONAL (BARBADOS) SRL (69 trademarks)

WELCHES
CHRIST CHURCH BB17154 , BB

Entity Type: 99

Trademark Details

Filing Date

March 9, 2011

Registration Date

December 9, 2014

Published for Opposition

September 23, 2014

Cancellation Date

July 16, 2021

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations and substances for the treatment of skin disorders, diseases, conditions and ailments; pharmaceutical preparations and products for use in dermatology; antifungal preparations; pharmaceutical preparations and substances for the treatment of eye disorders, diseases, conditions and ailments; pharmaceutical preparations and products for ophthalmological use; pharmaceutical preparations and substances for the treatment of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety, depression, depressive disorders and mental illness; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardiovascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Parkinson's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Huntington's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of amyotropic lateral sclerosis; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Alzheimer's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Tourette Syndrome; pharmaceutical preparations and substances for the prevention, treatment and alleviation of epilepsy; pharmaceutical preparations and substances for the prevention, treatment and alleviation of multiple sclerosis; pharmaceutical preparations and substances for the prevention, treatment and alleviation of cardio-pulmonary disorders, diseases, conditions, and ailments; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions, and ailments of the circulatory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension, high blood pressure, heart filure and ventricular dysfunction; pharmaceutical preparations and substances for the prevention, treatment and alleviation of metabolic disorders, diseases, conditions and ailments; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of viral and infectious diseases; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of central nervous system disorders, diseases, conditions and ailments, namely, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, cerebral palsy, insomnia, mood disorders, bipolar disorder, seizure disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the respiratory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the endocrine system; pharmaceutical preparations for the treatment of immunologic diseases, namely, auto immune motility diseases, immunologic deficiency syndromes, auto immune diseases, Acquired Immune Deficiency Syndrome (AIDS), hypersensitivity, allergies, tumors of the immunological organs; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the musculoskeletal system, namely, bone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; metformin; diltiazem; tramadol; carvedilol; bupropion; metoprolol; citalopram; zolpidem; fluoxetine; venlafaxine; lorazepam; and sumatriptan

Filing History

ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 18, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 18, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 18, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 18, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 18, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 18, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 18, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 18, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 11, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 11, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Apr 16, 2025 ASCK
CANCELLED SEC. 8 (6-YR)
Jul 16, 2021 C8..
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 3, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 3, 2020 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 3, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 3, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 3, 2020 COAR
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Dec 9, 2019 REM1
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jul 10, 2019 ASCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Mar 20, 2019 ASGN
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 16, 2018 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 16, 2018 REAP
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Feb 21, 2018 ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jan 11, 2017 ASGN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 3, 2016 TCCA
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jan 21, 2015 ASCK
REGISTERED-PRINCIPAL REGISTER
Dec 9, 2014 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 23, 2014 NPUB
PUBLISHED FOR OPPOSITION
Sep 23, 2014 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 3, 2014 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 19, 2014 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 18, 2014 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 30, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 30, 2014 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 30, 2014 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 14, 2014 GNRN
NON-FINAL ACTION E-MAILED
Feb 14, 2014 GNRT
NON-FINAL ACTION WRITTEN
Feb 14, 2014 CNRT
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 22, 2014 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 22, 2014 REAP
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jan 15, 2014 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jul 13, 2013 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jan 9, 2013 RCSC
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Aug 1, 2012 ASCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jul 6, 2012 GNS3
LETTER OF SUSPENSION E-MAILED
Jul 6, 2012 GNSL
SUSPENSION LETTER WRITTEN
Jul 6, 2012 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 27, 2012 TEME
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jun 27, 2012 RCSC
ASSIGNED TO LIE
Jun 27, 2012 ALIE
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 26, 2012 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jun 26, 2012 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 15, 2011 GNS3
LETTER OF SUSPENSION E-MAILED
Dec 15, 2011 GNSL
SUSPENSION LETTER WRITTEN
Dec 15, 2011 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 15, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 15, 2011 CRFA
ASSIGNED TO LIE
Dec 15, 2011 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 9, 2011 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 9, 2011 GNRN
NON-FINAL ACTION E-MAILED
Jun 9, 2011 GNRT
NON-FINAL ACTION WRITTEN
Jun 9, 2011 CNRT
ASSIGNED TO EXAMINER
Jun 9, 2011 DOCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 6, 2011 ASGN
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 14, 2011 NWOS
NEW APPLICATION ENTERED
Mar 12, 2011 NWAP